Access Pathways for Therapies Unfit for Commercialization Advance initiatives that support the development and implementation of therapies that are unlikely to be commercially viable but offer meaningful benefits for rare disease patients and their families.
Global Engagement Continue to build on international collaborations to increase access to innovative PRDCTs and improve pediatric rare disease outcomes in Canada.
Regulatory Pathways Identify policy objectives that promote a competitive Canadian regulatory environment aligned with international best practices and reduce barriers to pediatric rare disease treatments.
RareKids-CAN is committed to enabling timely access to pediatric rare disease therapies in Canada. Our third strategic priority is all about driving regulatory reform and system innovation.
Read more here
static1.squarespace.com/static/662c1...
#RareDiseaseResearch #PediatricRareDiseases
